DiscoveryProbe™ FDA-approved Drug Library: High-Throughput Screening and Drug Repositioning Resource

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (L1021) comprises 2,320 bioactive compounds approved by major regulatory agencies including the FDA, EMA, HMA, CFDA, and PMDA (APExBIO). Compounds within the collection cover a broad spectrum of mechanisms, such as receptor agonism/antagonism, enzyme inhibition, and ion channel modulation (APExBIO). The library is validated for high-throughput (HTS) and high-content screening (HCS) applications, supporting drug repositioning and novel target discovery (see mechanisms overview). Representative drugs include doxorubicin, metformin, atorvastatin, and canagliflozin, the latter recently identified as an HDAC6 inhibitor for anti-metastatic cancer research (Jiang & Ma, 2022). The compounds are delivered as 10 mM DMSO solutions, stable for 12 months at -20°C or 24 months at -80°C, facilitating standardization and reproducibility (APExBIO).

Biological Rationale

Drug discovery increasingly leverages libraries of clinically approved compounds to expedite the identification of new therapeutic uses. This approach, termed drug repositioning, capitalizes on established safety and pharmacokinetic profiles. The DiscoveryProbe™ FDA-approved Drug Library enables systematic interrogation of disease models, including oncology, neurodegeneration, and metabolic disorders, by providing direct access to molecules with known mechanisms of action (mechanisms, benchmarks).

Enzyme inhibition, receptor modulation, and ion channel regulation are well-characterized pharmacological strategies represented in this library. For example, HDAC6 inhibition, as performed by canagliflozin, has emerged as a targeted mechanism for reducing metastasis in gastric cancer models (Jiang & Ma, 2022). Applying a collection of FDA-approved molecules in high-content and high-throughput screens enables parallel evaluation of multiple pathways, streamlining the path from bench to bedside.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ FDA-approved Drug Library contains compounds with diverse and well-documented mechanisms. These include:

• Receptor agonists/antagonists: Target G protein-coupled receptors, nuclear receptors, and others (e.g., metformin as an AMPK activator).
• Enzyme inhibitors: Inhibit kinases, HDACs, proteases, and metabolic enzymes (e.g., canagliflozin as an SGLT2 and HDAC6 inhibitor).
• Ion channel modulators: Modify channel gating and conductance, affecting neuronal and cardiac excitability.
• Signal pathway regulators: Impact pathways such as mTOR, WNT/β-catenin, and PPARγ (see mechanistic review for pathway-specific applications).

This diversity supports hypothesis-driven screening and unbiased phenotypic assays, facilitating the identification of both on-target and off-target effects. Each compound is supplied as a 10 mM solution in DMSO, enabling direct use in biochemical or cell-based assays without further solubilization.

Evidence & Benchmarks

• Canagliflozin was identified from the DiscoveryProbe™ FDA-approved Drug Library as a potent HDAC6 inhibitor using enzymatic, SPR, and CETSA assays (Jiang & Ma, 2022, https://doi.org/10.3389/fonc.2022.1057455).
• The library supports high-throughput screening (HTS) and high-content screening (HCS) workflows in 96-well and deep-well plate formats, as validated in multiple peer-reviewed studies (HTS best practices).
• Drugs in the collection have defined stability (12 months at -20°C, 24 months at -80°C) and are supplied in DMSO to ensure reproducibility (APExBIO product documentation, product page).
• Repositioning screens using this library have uncovered new modulators of OSCAR-PPARγ signaling and other disease-relevant targets (mechanistic review).
• Applications in oncology, neurodegeneration, and metabolic disease research have been reported, demonstrating broad utility for target identification and validation (mechanisms, benchmarks).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is optimized for multiple research applications:

• Cancer research drug screening: Enables rapid identification of compounds modulating tumor growth, metastasis, or resistance pathways (see canagliflozin and HDAC6 inhibition).
• Neurodegenerative disease drug discovery: Facilitates screening for neuroprotective or neuroregenerative compounds targeting known signaling cascades.
• Signal pathway regulation and enzyme inhibitor screening: Supports pathway-centric and enzyme-focused screens for mechanistic validation.
• Drug repositioning screening: Expedites translation of existing drugs to novel indications based on robust pharmacological data.
• Pharmacological target identification: Permits systematic deconvolution of phenotypic screen hits by reference to known mechanisms.

For a detailed discussion of best practices and practical strategies in cell-based assays, see this scenario-driven article, which the current article extends by outlining new mechanistic discoveries and regulatory benchmarks.

Common Pitfalls or Misconceptions

• The library is not intended for clinical use; all compounds are for research purposes only.
• Not all compounds are active in every disease model; context-specific validation is required.
• Some compounds may exhibit off-target effects, necessitating secondary validation.
• DMSO concentrations above 0.5% in cell culture may cause cytotoxicity; dilution is essential.
• The library does not replace comprehensive ADMET profiling for new indications.

Workflow Integration & Parameters

APExBIO supplies the DiscoveryProbe™ FDA-approved Drug Library in 96-well microplates, deep-well plates, or 2D barcoded screw-top tubes. Standard concentration is 10 mM in DMSO. Compounds are stable for 12 months at -20°C and up to 24 months at -80°C. Shipping is performed on blue ice for evaluation samples and at room temperature or blue ice for larger orders. For high-throughput screening, recommended working concentrations are typically 1–20 μM, with DMSO kept below 0.5% in assay wells to minimize toxicity (workflow Q&A).

The L1021 kit is directly compatible with automated liquid handling systems and imaging-based HCS platforms, supporting both endpoint and kinetic readouts. Detailed scenario-driven integration examples are provided in this practical article, which the current overview clarifies by specifying regulatory origins and molecular diversity.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) from APExBIO is a validated, comprehensive resource for high-throughput and high-content drug screening, target identification, and repositioning studies. Inclusion of regulatory agency-approved compounds with known mechanisms accelerates translational research across cancer, neurodegenerative, and metabolic disease models. Ongoing updates in compound annotation and best practices further enhance its impact on precision pharmacology. For detailed specifications or to request the L1021 kit, see the DiscoveryProbe™ FDA-approved Drug Library product page.